Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DOE7C4
|
|||
| Drug Name |
GSK3389404
|
|||
| Synonyms |
IONIS-HBV-LRX
Click to Show/Hide
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Hepatitis B [ICD-11: 1E51; ICD-10: B18.1] | Phase 2 | [1] | |
| Company |
GlaxoSmithKline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03020745) A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects. U.S. National Institutes of Health. | |||
| REF 2 | A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects. Clin Pharmacol Drug Dev. 2019 Aug;8(6):790-801. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.